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ABSTRACT
Objectives: This clinical study was conducted to determine the hemostasis profile and clinical outcome of acute ischemic stroke patients treated with 
DLBS1033 in comparison with aspirin or clopidogrel. DLBS1033 is a proprietary bioactive protein fraction derived from the earthworms (Lumbricus 
rubellus) that possesses both fibrinolytic and antithrombotic properties.
Methods: This was a 3-arm, parallel, randomized, controlled, open-label, blinded-evaluation study involving 126 acute ischemic stroke patients. Each 
subject received any of the following study medication within 96 hrs after the stroke onset: Aspirin 80 mg daily (Group 1), or clopidogrel 75 mg daily 
(Group 2), DLBS1033 490 mg 3 times daily (Group 3), for 90 days. Hemostasis parameters evaluated were prothrombin time (PT), activated partial 
thromboplastin time (aPTT), and international normalized ratio (INR), while the clinical outcomes were measured using Gadjah Mada Stroke Scale 
(SSGM) and Barthel index (BI).
Results: Baseline characteristics, including the hemostasis and clinical profiles, were comparable between groups. At the end of the study, PT, aPTT, 
and INR values were not significantly different between groups, which were all within the normal ranges. There was a significant improvement of BI 
as well as SSGM from baseline in each group. The improvement size of BI was found similar between groups (p=0.098). However, a significantly better 
improvement of SSGM was observed in those received DLBS1033 (6.98±4.90; p=0.001 vs. aspirin [3.74±3.66], p=0.006 vs. clopidogrel [4.26±4.21]).
Conclusion: It was concluded that DLBS1033 provided a safe hemostasis profile (PT, aPTT, and INR) comparable to that of aspirin or clopidogrel in 
ischemic stroke patients. Treatment with DLBS1033 improved clinical outcomes indicated by the BI and SSGM, and the improvement size of SSGM was 
even better than that of aspirin or clopidogrel treatment.
Keywords: Acute ischemic stroke, Barthel index, DLBS1033, Hemostasis, Gadjah Mada Stroke Scale, Oral lumbrokinase.
INTRODUCTION
Thrombosis remains involved in the pathological course of some most 
common vascular diseases, including ischemic stroke [1,2]. Substantial 
progress has been made in understanding the biology of thrombus 
formation and the pathophysiology of thrombosis. Several more established 
pharmacologic agents, including thrombolytic therapy, antiplatelet agents, 
and anticoagulants, have been recommended for the early management 
of acute ischemic stroke [3]. However, all the recommended, as well as 
neuro-protective agents available for prevention or treatment that have 
been in use for decades, have currently been replaced with newer variants 
that offer a modest incremental improvement [4-10]. Yet, the ideal drug 
for prophylaxis and treatment of thrombotic disease that will inhibit 
the thrombosis but not the hemostasis remains scarce. This situation is 
complicated further by the emerging resistance to therapy with the most 
established antiplatelets, aspirin, and clopidogrel that brings potentially 
severe consequences such as recurrent myocardial infarction, stroke, or 
death [11-13]. Such a reduced sensitivity to antiplatelet drugs was even 
reported to be more remarkable in diabetic as compared to non-diabetic 
patients [14]. Thus, an expedite translation of new knowledge from “test-
tube,” and animal studies to bedside pharmaceutical development should 
be pursued for new and more strategic advances in the prevention of 
thrombotic diseases.
For thousands of years, earthworms have widely been used in Indonesia, 
China, Japan, and the Far East to treat various chronic diseases. 
A group of serine protease enzymes collectively called lumbrokinase 
extracted from the earthworms of Lumbricidae family could directly 
dissolve fibrin and activate plasminogen [15,16]. Lumbrokinase 
possesses strong fibrinolytic and fibrinogenolytic properties, lowers 
blood viscosity, markedly inhibits platelet aggregation, and promotes 
thrombus degradation without causing excessive bleeding [17-19]. 
Lumbrokinase is stable over a wide range of pH and temperature; thus, 
it can be administered orally [20].
DLBS1033 investigated in this clinical study is a lumbrokinase 
fractionated from the earthworms, Lumbricus rubellus, through a 
proprietary technology of extraction. DLBS1033 possesses eight 
major proteins, each with a molecular weight below 100 kDa, named 
as Lumbricus low-molecular-weight proteins [21]. This specific 
pattern of proteins confers a unique characteristic of DLBS1033 
with its mechanism of action as an antithrombotic and thrombolytic 
agent. The antithrombotic and thrombolytic activities of the bioactive 
protein fraction have been demonstrated in vitro and ex vivo [21]. 
Furthermore, DLBS1033 has also been proven for its safety profile, 
through toxicological studies in animal [22], and safety studies in 
human [23,24]. To date, DLBS1033 has been approved by National 
Agency of Drug and Food Control, Republic of Indonesia, to be marketed 
as Indonesian standardized herbal medicine. Since then, no clinically 
significant adverse drug reactions have been reported.
This current study was conducted to investigate whether the virtues 
of DLBS1033 that have been demonstrated preclinically would also 
be translated into clinical benefits for ischemic stroke patients. In this 
study, we evaluated the hemostasis profile as well as functional and 
neurological outcomes of ischemic stroke patients receiving DLBS1033, 
in comparison with the more established antiplatelet agents used in 
such cases, aspirin and clopidogrel.
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This study was conducted in compliance with the Declaration of 
Helsinki and the Good Clinical Practice. The study protocol was 
reviewed and approved by the Independent Ethics Committee of 
Gadjah Mada University, Yogyakarta, Indonesia, prior to trial initiation. 
This was a 3-arm, parallel, randomized, controlled, open-label, 
blinded-evaluation (PROBE-designed) clinical study, over 90 days of 
treatment, to determine the hemostasis profile as well as functional 
and neurological outcomes of ischemic stroke patients. Eligible subjects 
were randomly allocated to receive any of the following regimens: 
Aspirin 80 mg once daily (Group 1, Aspirin), clopidogrel 75 mg once 
daily (Group 2, Clopidogrel), or DLBS1033 490 mg three times daily 
(Group 3, DLBS1033). In this study, both aspirin and clopidogrel served 
as the positive controls to examine the efficacy and safety of the new 
treatment with DLBS1033.
Subjects were acute ischemic stroke patients admitted in the Stroke 
Unit or Neurology-Ward of the Central General Hospital Dr. Sardjito 
Yogyakarta, Indonesia. The inclusion criteria included: (1) adult male 
or female; (2) acute ischemic stroke diagnosed by cranial CT-scan; 
(3) having admitted in the hospital within less than 96 hrs after the 
onset of stroke; and (4) willingness to participate in the study and give 
subject’s written informed consent. The patients were excluded if any 
of the following criteria was met: (1) recurrent stroke; (2) transient 
ischemic attack; (3) intra-cerebral or subarachnoid hemorrhagic stroke; 
(4) undefinable stroke onset; (5) regular therapy with antiplatelets, 
anticoagulants; (6) hemostasis or coagulation disorders; (7) major 
surgery within the last 6 months or having to have a surgery within 
the next 3 months; (8) renal impairment defined as serum creatinine 
level >3× upper limit of normal or history of hemodialysis; (9) systemic 
inflammatory response syndrome; (10) unconsciousness; or 
(11) uncontrolled hypertension (systolic blood pressure > 185 mmHg 
or diastolic blood pressure > 110 mmHg).
Subjects were withdrawn from the study if any of the following 
conditions applied during the course of the subject’s participation: 
(1) Worsened prognosis, unconsciousness, and neurological deficits; 
(2) hypersensitive to any of the study medication; (3) bleeding adverse 
events, including nausea and vomiting, severe headache, gastrointestinal 
pain, hematoma, and any of bleeding signs; and (3) subjects were 
suffering from any disease, including physical accidents that would 
interfere with the evaluation of the hemostasis profile.
Study medication
The management of acute ischemic stroke in the Unit Stroke of 
Dr. Sardjito Yogyakarta Hospital was in accordance with the acquired 
hemophilia A (AHA)/ASA Guidelines for the Early The Management 
of Patients with acute ischemic stroke.3 Aspirin (Thrombo Aspilets® 
enteric-coated tablets, Medifarma Laboratories Inc., Jakarta, Indonesia) 
at the dose of 80 mg once daily, clopidogrel (Vaclo® film-coated 
tablets, Dexa Medica, Palembang, Indonesia) 75 mg [25], once daily, 
or DLBS1033 490 mg (Disolf® enteric-coated tablets, Dexa Medica, 
Palembang, Indonesia) three times daily was initially administered to 
the eligible subjects within 96 hrs after the stroke onset, to be taken 
for the next 90 days. Concomitant medications taken by study subjects 
along the study were valsartan 80/160 mg daily and/or amlodipin 
5/10 mg daily (by hypertensive subjects); (2) insulin therapy (by 
diabetic subjects); (3) simvastatin 20 mg daily (all subjects); and (4) oral 
citicholine 1000 mg twice daily (all subjects). After study completion, 
subjects continued their therapy in accordance with the management 
for ischemic stroke applicable in the hospital.
Characterization of DLBS1033 was as previously described by Trisina 
et al. [21]. A pharmaceutical study has also been conducted to support 
its oral enteric-coated formulation and dosing regimen [26].
Randomization code was prepared using the permuted 3-block-
allocation and random numbers generator. In order to keep the 
blinded-evaluation procedures, the study products were administered 
by a particularly designated nurse, and the Investigator who evaluated 
the outcomes was blind of the subject allocation. Blinding codes 
were disclosed when the study had been completed, and trial-related 
database had been frozen.
Hemostasis profile and clinical outcomes
Hemostasis parameters evaluated in this study were prothrombin time 
(PT), activated partial thromboplastin time (aPTT), and international 
normalized ratio (INR). Adverse events were observed and recorded 
during the study conduct. The aPTT is an appropriate parameter to 
evaluate the intrinsic and common pathways of the coagulation cascade. 
The PT (or can be expressed as INR) evaluates the extrinsic and common 
pathways [27]. Therefore, measurement of PT (or INR), or aPTT can be 
beneficial to detect the abnormal steps in the coagulation cascade, for the 
diagnosis of coagulation disorders [28]. Since we expected that therapy 
with DLBS1033 as an antithrombotic/thrombolytic agent should not 
impair the hemostasis profile, we hypothesized that the bioactive fraction 
would not significantly interfere with those coagulation parameters.
The functional outcomes evaluated in this study were Barthel index 
(BI) [29-33]. All variables were measured at baseline (day 0, before 
study medication) and day 90 (end of study). The BI is based on a rating 
scale that is completed by an observer, and it has a good inter-rater 
reliability [30]. The items can be divided into a group that is related to 
self-care (feeding, grooming, bathing, dressing, bowel and bladder care, 
and toilet use) and a group related to mobility (ambulation, transfers, 
and stair climbing). A total of 10 activities are scored, and the values are 
then added to give a total score ranging from 0 (totally dependent) to 100 
(completely independent). Lower scores indicate greater dependency. 
Scoring on the BI can be interpreted as follows: Independent (BI score 
of 80-100), needs minimal help (60-79), partially dependent (40-59), 
very dependent (20-39), and totally dependent (<20). The BI measures 
what the patient actually does rather than what they can do [30-32].
Neurological outcome in this study was measured by the validated 
Gadjah Mada Stroke Scale (SSGM) [34]. The SSGM consists of 14 items, 
including level of consciousness, orientation, language, visual field, eye 
movement, facial movement, motoric function of the arms and limbs 
both the passive and active (affected) sides, each of which is scored 0 
(severe impairment) to 2 or 3 (normal, without impairment), resulting 
in a total score ranging from 0 (the most severe neurological deficit) 
to 38 (complete recovery) as shown in Table 1. The interpretation of 
the SSGM is that a score of ≥23 means mild to moderate neurological 
deficits, and a score of <23 means severe neurological deficits [34].
Statistical analysis
Demography and baseline characteristics were tabulated and 
summarized by the group. Analyzes on hemostatic parameters as well as 
clinical outcomes were carried out on intent-to-treat (ITT) population, 
consisting of all patients who were randomized, exposed to at least one 
dose of the study product, and then returned for at least one visit after 
treatment-initiation. This would include data from withdrawn subjects.
All of the data are expressed as mean±standard deviation unless 
otherwise is specified. Comparability of baseline characteristics 
between groups was statistically analyzed by Kruskal–Wallis and Chi-
square, for continuous and categorical data, respectively. Hemostasis 
and efficacy parameters (PT, aPTT, INR, SSGM, and BI) were statistically 
analyzed between groups using Kruskal–Wallis and within-group using 
Wilcoxon signed-rank. All statistical tests were at 5% significance level. 
The SPSS® version 14.0 was used for the analyzes.
RESULTS
The clinical study had been conducted in the Stroke Unit or Neurology-
Ward of the Central General Hospital Dr. Sardjito Yogyakarta since May 
2012 until December 2013. A total of 129 subjects were enrolled and 
randomly allocated into any of the 3 arms, each of which consisted of 
43 subjects. Of 129 subjects, only 126 were available for ITT analysis. 
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Three subjects (one subject in each group) moved out of town and were 
lost to follow-up. They did not have any post-treatment data, thus were 
not evaluable.
Baseline characteristics of the study subjects were comparable between 
groups as shown in Table 2. In all groups, subjects were aged between 
50 and 65 years old, with male predominance (around 70% of subjects 
in each group).
Onset of stroke, BI, PT, aPTT, and INR, as well as other risk factors, such 
as plasma glucose, lipid profile, blood pressure, were also comparable 
between groups at baseline. In terms of SSGM, at baseline, subjects in 
DLBS1033 Group showed a slightly lower (worse) score (p=0.030) than 
those in the aspirin group. Therefore, the real between-group difference 
in neurological outcome was also evaluated by comparing the size of 
improvement of SSGM from baseline, in addition to the final score of 
SSGM at the end of study.
Table 1: SSGM [34]
Tested item Responses and scores
Level of consciousness 3 - Alert
2 - Drowsy, somnolent
1 - Obtunded, stupor
0 - Coma/unresponsive
Orientation (time, space, people) questions 3 - Answers each of all three questions correctly
2 - Answers two of three questions correctly
1 - Answers one of three questions correctly
0 - Answers neither correctly
Articulation 3 - Normal
2 - Mild dysarthria
1 - Severe dysarthria
0 - Mute or global aphasia
Gaze 3 - Normal horizontal movements
2 - Eyeball in medial position, able to deviate to either side
1 - Eyeball in lateral position, able to return to medial position
0 - Complete gaze palsy (conjugate deviation)
Facial movement 2 - Normal
1 - Partial facial weakness (paresis)
0 - Complete unilateral palsy (paralysis)
Visual fields 2 - Normal
1 - Partial hemanopia
0 - Complete hemanopia
Arm’s motoric function - Passive (unaffected side) 3 - No drift
Examiner raises both subject’s arms to a position of 45° 
(if the subject is in a supine position), or 90° (if seated). 
Subject is asked to hold such a position for 10 seconds
2 - Falls before10 seconds
1 - Unable to hold, but performs noticeable effort against gravity
0 - No effort against gravity
Arm’s motor function - Active (affected side) 3 - Able to raise perfectly
Examiner raises both subject’s arms to a position of 45° 
(if the subject is in a supine position), or 90° (if seated). 
Subject is asked to hold such a position for 10 seconds
2 - Able to raise
1 - Able to raise with flexed arm
0 - No movement
Extension of wrist 3 - Full extension, full strength
2 - Full extension, less strength
1 - Partial extension
0 - Unable to extend
Fingers strength 2 - Balanced strength of both hands
Subject is asked to perform pinch (squeeze between 
the finger and thumb) with both hands, and the 
examiner has to release the squeeze with one finger
1- Less strength on the affected hand
0 - Unable to perform pinching
Limb’s motoric function - Passive (unaffected side) 3 - No drift
Examiner raises both subject’s limbs to a position of 30° 
(with the subject in a supine position). Subject is asked 
to hold such a position for 5 seconds
2 - Falls before 5 seconds
1 - Unable to hold, but performs noticeable effort against gravity
0 - No effort against gravity
Limb’s motoric function - Active (affected side) 2 - Full flexion
Subject is asked to perform thigh and knee flexion 1 - Partial flexion
0 - No flexion
Dorsiflexion 2 - Normal strength to perform dorsiflexion
1 - Less strength to perform dorsiflexion 
0 - Unable to perform dorsiflexion
Gait 4 - Walks 5 m long without aid or other person’s assistance
3 - Walks with aid (no assistance from other person)
2 - Walks with assistance from other person
1 - Unable to walk, but able to stand with aid
0 - Neither walks or stands
SSGM: Gadjah Mada Stroke Scale
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After 90 days of treatment, we found no difference in hemostasis 
profile between groups as shown by PT, aPTT, and INR values (Table 3). 
Within-group analysis showed that there was a bit of shortened PT 
with DLBS1033, but of no clinical importance. The aPTT and INR in 
each group did not change from their respective baseline values. All 
measured hemostasis parameters in each group remained within their 
respective normal ranges.
Hemostasis profile at the end of the study demonstrated that 
administration of DLBS1033 at the dose of 3 × 490 mg daily for 90 days 
in ischemic stroke subjects was safe and comparable to aspirin 80 mg 
daily or clopidogrel 75 mg daily. There was no significant prolongation 
of hemostasis parameters found. Neither were there bleeding adverse 
events in any groups observed during the study conduct.
All subjects in all groups received simvastatin 20 mg daily and 
citicholine 1000 mg twice daily during the study participation. For the 
antihypertensive agents, subjects might receive amlodipine, valsartan 
or a combination of both, depending on their individual condition. All 
diabetic subjects received insulin therapy.
In terms of clinical outcome, each group demonstrated a significant 
improvement of BI (p<0.001) from baseline to day 90, with a 
mean score of >85 in all groups at the end of study. The greatest 
improvement was observed in DLBS1033 Group, with the size of 
improvement of 23.09±19.16 from baseline, but it was not significantly 
different (p=0.098) with that of aspirin (15.12±15.71) or clopidogrel 
(17.98±19.03), as shown in Fig. 1.
In line with the improvement of BI, DLBS1033 Group demonstrated 
the greatest improvement of SSGM (6.98±4.90) from baseline that was 
also significantly greater (p=0.002) than that of aspirin (3.74±3.66) or 
Clopidogrel (4.26±4.21) (Fig. 2).
We also found there were similar percentages of subject in DLBS1033 
Group (83.3% and 100%) to those in aspirin (92.9% and 100%) who 
achieved BI of ≥85 and SSGM of ≥23, respectively, at the end of study; 
both of which were slightly higher than those in clopidogrel (73.8% and 
97.6%, respectively), even though they were not statistically different 
(Fig. 3). Compared to aspirin, treatment with DLBS1033 for 90 days 
seemed to be effectively comparable in achieving BI ≥85 (odds ratio 
Table 2: Baseline characteristics
Variable Group 1 Aspirin (n=42) Group 2 Clopidogrel (n=42) Group 3 DLBS1033 (n=42) p‡
Age (year) 58.81±9.40 62.45±10.54 61.29±8.73 0.210
Gender (%)
Male 31 (73.8) 29 (69.0) 31 (73.%) 0.854
Female 11 (26.2) 13 (31.0) 11 (26.2)
Onset of stroke (hours before 
initial dose of study medication)
25.26±32.85 23.24±26.75 33.52±47.41 0.399
Blood pressure (mmHg)
Systolic 166.90±35.97 162.74±26.09 168.45±29.39 0.570
Diastolic 98.69±18.45 93.93±11.77 95.60±13.58 0.356
Concomitant diseases (%)
Hypertension 22 (52.4) 15 (35.7) 21 (50.0) 0.253
Diabetes mellitus 18 (42.9) 14 (33.3) 19 (45.2) 0.501
Dyslipidemia 32 (76.2) 24 (57.1) 20 (47.6) 0.024*
Concomitant medication (%)
Amlodipine 15 (35.7) 10 (23.8) 13 (31.0) 0.489
Valsartan 11 (26.2) 6 (14.3) 11 (26.2) 0.317
Insulin 18 (42.9) 14 (33.3) 19 (45.2) 0.501
Clinical outcomes
Barthel index 81.43±23.07 73.57±28.14 71.55±27.42 0.262
SSGM 32.05±5.66 29.64±7.37 28.52±6.67 0.030*
Laboratoric parameters
FPG (mg/dl) 143.36±68.44 144.36±80.23 141.74±69.03 0.927
Hemoglobin (g/dl) 14.58±1.52 13.88±1.76 14.28±1.57 0.365
Total cholesterol (mg/dl) 226.21±43.84 217.69±48.02 214.28±45.61 0.222
HDL (mg/dl) 42.81±9.36 43.71±11.96 44.41±9.99 0.876
LDL (mg/dl) 160.08±36.74 140.79±35.63 142.24±32.03 0.044*
Triglyceride (mg/dl) 173.40±90.83 154.17±80.92 147.27±61.66 0.559
BUN (mg/dl) 13.10±3.93 12.55±3.18 12.80±3.07 0.908
Serum creatinin (mg/dl) 1.23±0.70 1.17±0.41 1.09±0.51 0.766
Uric acid (mg/dl) 6.48±1.42 6.20±1.72 6.50±1.50 0.748
PT (seconds) 12.98±1.22 13.07±1.15 13.09±1.29 0.866
aPTT (seconds) 29.66±1.22 29.39±3.39 29.65±4.73 0.978
INR 0.94±0.16 0.93±0.13 0.97±0.15 0.545
Continuous data are expressed in mean±SD. Categorical data are expressed in a number of subjects (n) and percentage (%). ‡Between-group analysis: Categorical 
variables were analyzed using Chi-square; while the continuous ones using Kruskal–Wallis. aPTT: Activated partial thromboplastin time, BUN: Blood urea nitrogen, 
FPG: Fasting plasma glucose, HDL: High-density lipoprotein cholesterol, INR: International normalized ratio, LDL: Low-density lipoprotein cholesterol, PT: Prothrombin 
time, SSGM: Gadjah Mada Stroke Scale, SD: Standard deviation
Table 3: Hemostasis profile between groups at baseline and day 90
Hemostasis profile Baseline p‡ Day 90 p‡ p†
PT (second)
Aspirin (n=42) 12.98±1.22 0.866 12.36±1.39 0.788 0.080
Clopidogrel (n=42) 13.07±1.15 12.53±1.19 0.076
DLBS1033 (n=42) 13.09±1.29 12.67±1.55 0.039*
aPTT (second)
Aspirin (n=42) 29.66±5.49 0.978 29.59±4.25 0.619 0.523
Clopidogrel (n=42) 29.39±3.39 29.96±4.16 0.302
DLBS1033 (n=42) 29.65±4.73 30.54±4.41 0.096
INR
Aspirin (n=42) 0.94±0.16 0.545 0.94±0.13 0.154 0.318
Clopidogrel (n=42) 0.93±0.13 0.96±0.11 0.051
DLBS1033 (n=42) 0.97±0.15 0.99±0.13 0.132
Data are expressed in mean±SD. †Within-group analysis using Wilcoxon 
Signed-Rank. ‡Between-group analysis using Kruskal–Wallis. *Statistically 
significant (p<0.05). aPTT: Activated partial thromboplastin time, 
INR: International normalized ratio, PT: Prothrombin time, SSGM: Gadjah 
Mada Stroke Scale, SD: Standard deviation
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[OR]=0.38; 95% confidence interval [CI], 0.09-1.60; p=0.189). That 
was also the case with DLBS1033 in comparison with clopidogrel 
(OR= 1.77; 95% CI, 0.61-5.14; p=0.291). DLBS1033 treatment was 
also effectively comparable in achieving SSGM ≥23, either compared 
to aspirin (OR=1.00; 95% CI, 0.019-51.57; p=1.000) or clopidogrel 
(OR=3.07; 95% CI, 0.12-77.60; p=0.496).
DISCUSSION
This study demonstrated that DLBS1033 therapy in ischemic stroke 
patients provided a safe hemostatic profile, which was comparable 
to that of aspirin or clopidogrel therapy (Table 3). All measured 
parameters, i.e., PT, aPTT, and INR, were within the normal range at the 
Fig. 1: Effect of aspirin, clopidogrel, and DLBS1033 treatment on the functional outcome measured by Barthel index. The error bars 
represent the standard errors; Wilcoxon signed-rank was used in within-group analysis; Kruskal–Wallis was used in between-group 
analysis
Fig. 2. Effect of aspirin, clopidogrel, and DLBS1033 treatment on the neurological outcome measured by Gadjah Mada Stroke Scale. The 
error bars represent the standard errors; Wilcoxon signed-rank was used in within-group analysis; Kruskal–Wallis was used in between-
group analysis
Fig. 3: Proportion of subjects with Bathel index ≥85 (left) and Gadjah Mada Stroke Scale ≥23 (right)
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end of the study, suggesting that there were no deficient coagulation 
factors observed during therapy with DLBS1033, aspirin, and 
clopidogrel. Furthermore, the result of this study also indicates that the 
risk for bleeding due to the administration of DLBS1033 was evidently 
low, similar to that of aspirin or clopidogrel at their respective usual 
dose regimen. This was also clinically proven by zero bleeding event 
in all groups observed during the study conduct. The safety profile of 
DLBS1033 was aligned to that reported by Zhang in a former study with 
a similar protease enzymes, lumbrokinase [20], demonstrating that the 
proteases did not affect hemostasis profile measured by PT or aPTT, 
thus did not interfere with the INR.
With respect to aspirin and clopidogrel treatment, our current 
3-month-study showed no prolongation of aPTT. Neither did it show the 
increase of INR nor any bleeding events. This was somewhat different 
with a former report by Tamura et al, in which aspirin and clopidogrel 
treatment were reported associated with bleeding complications 
(hemorrhage, melaena, and hematochezia). Aspirin was also reported 
associated with prolongation of aPTT, but not with increased INR. 
While clopidogrel treatment was associated neither with prolongation 
of aPTT nor increased INR [35]. However, in the report, aspirin might be 
used concomitantly with warfarin and/or clopidgrel and for a long-term 
therapy as well, while the observation in our study was limited only 
to the first 3 months of therapy. That may explain the difference with 
the former report. In this study, we found neither clinically significant 
bleeding events nor adverse changes of the laboratory hemostatic 
parameters. A case study also reported that clopidogrel treatment was 
associated with prolonged aPTT and induced AHA in a patient with 
cerebellar infarction, but the mechanism of how the drug could induce 
the event is unknown [36], and thus, the adverse effect was likely to be 
an anecdotal case.
In addition to its promisingly safe hemostatic profile, DLBS1033 also 
improved the clinical outcomes. A significant improvement of BI from 
baseline occurred in each treatment group. The improvement was 
similar across all groups (Fig. 2). This result suggested that DLBS1033 
was as efficacious as aspirin or clopidogrel in improving functional 
outcome of patients with ischemic stroke. This study also demonstrated 
that DLBS1033 treatment was effectively comparable to aspirin or 
clopidogrel in achieving BI of ≥85 that means DLBS1033 treatment 
effectively improved subjects’ daily performance from disability or 
necessity for other people’s assistance to becoming independence. 
A score of 85 of BI usually corresponded to independence with minimal 
assistance that the majority of patients were able to get dressed and to 
move from armchair to bed without assistance [37]. Score of <85 also 
corresponded to a dependent state in which patients reported needing 
assistance in performing daily living activities, with a sensitivity of 94-
95% and a specificity of 80-86% [38-40].
Further, even though that the efficacy of DLBS1033 treatment seemed 
to be comparable to aspirin or clopidogrel in achieving SSGM of ≥23, 
the size of improvement of the neurological function was significantly 
greater with DLBS1033 than that with aspirin or clopidogrel (Fig. 2).
In this study, the improvement of both functional and neurological 
outcome with DLBS1033 treatment was likely due to DLBS1033 
activities as both the antithrombotic and thrombolytic agent [21,41]. 
In vitro studies demonstrated reduced expression of several genes 
involved in inflammatory and atherogenic reaction by DLBS1033, 
such as nuclear factor kappa B (NF-κB), tumor necrosis factor-alpha 
(TNF-α), vascular cell adhesion molecule-1 (VCAM-1), and P-selectin. 
The down-regulation of NF-κB has a link to the inhibition of atheroma 
formation, suggesting that DLBS1033 works as an anti-atherogenesis 
agent. DLBS1033 can inhibit the progression of other cytokines that 
are activated by TNF-α and adherence of leukocytes to endothelium. 
Activity of DLBS1033 in decreasing the expression of P-selectin may be 
related to the suppression of de novo synthesis of P-selectin mediated by 
cytokine. DLBS1033 suppressed the expression of VCAM-1, a member 
of the immunoglobulin gene superfamily that mediates leukocyte 
binding to the endothelial cell. In the same study, it was shown that 
DLBS1033 suppressed the expression of MMP-9 gene, a marker of 
plaque instability, suggesting that this bioactive protein fraction has 
the ability to control plaque stabilization. MMP-9 is a protease that 
degrades extracellular matrix proteins including gelatin, collagen, 
elastin, and laminin that are important in tissue destruction; and 
also in tissue remodeling and inflammation. This study indicated that 
DLBS1033 could regulate the uncontrolled event of plaque rupture by 
inhibiting the expression of MMP-9 [21,41]. Our current clinical findings 
indicate that DLBS1033 is promising in accommodating the necessity 
of treatment for acute ischemic diseases, due to its dual features Asan 
antiplatelet and thrombolytic agent and the oral formulation offers 
more practical administration.
Due to the limited scope of our study, we did not discuss to what extent 
other variables such as age, NIHSS score at admission, cardio-/cerebro-
vascular history (such as myocardial infarction and stroke), dementia, 
socio-economic status, presence of fever, undernutrition, as were also 
reported in former studies [42-47], might influence the outcomes. 
However, random allocation applied in this study allowed a comparable 
distribution of those confounding factors between groups; therefore, 
a valid and reliable interpretation could still be made as previously 
discussed.
CONCLUSIONS
The study concluded that treatment with DLBS1033 at the dose 
of 490 mg 3 times daily for 90 days in ischemic stroke subjects 
demonstrated a safe hemostatic profile, which was comparable to that 
of aspirin 80 mg once daily or clopidogrel 75 mg once daily. In terms 
of functional and neurological outcomes, the study indicated that 
DLBS1033 clinically benefitted the ischemic stroke subjects.
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